中文字幕五月香久久婷伊人人妻高清免费中文字幕|中文字幕二区三区|中文字幕av一区二区三区佐山爱|色综合久久久久久久久五月|88国产精品欧美一区二区三区|日韩精品中文字幕在线播放|日韩内射在线观看|日韩av第二页|果冻传媒天美传媒在|午夜麻豆视频,亚洲精品日韩三区,中出人妻中文字幕91在线,噜噜吧色

News On Bispecific Antibodies

2017-12-21 14:34:27 78

M802 bispecific antibody binds to a tumor target and an immune target simultaneously to recognize and link cancer cells and immune cells, subsequently forms an effective tumor-immune cell complex in co-stimulation and induction of cytokine release, resulting recruiting of immune cells and killing of tumor cells. 

M802 is intended to be used to treat metastatic breast cancer, gastric cancer and other malignant tumors express HER2, and it is expected to solve the unmet medical needs of HER2 monoclonal antibody in aspects of narrow indications, susceptibility to relapse, metastasis and high cost. 

Bispecific antibody can combine two different antigens at the same time, breaking the bottleneck of monoclonal antibody in target selection, and it is the important development direction of new generation antibody drug. The development of bispecific antibody drugs in China has also been emerging rapidly, with the global biotech company investing heavily bispecific antibodies-based medicines.